	US 12,275,746 B2
	Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists
Ramakrishna Nirogi, Hyderabad (IN); Anil Karbhari Shinde, Hyderabad (IN); Abdul Rasheed Mohammed, Hyderabad (IN); Vinod Kumar Goyal, Hyderabad (IN); Santosh Kumar Pandey, Hyderabad (IN); Vijay Sidram Benade, Hyderabad (IN); Venkatesh Goura, Hyderabad (IN); and Venkateswarlu Jasti, Hyderabad (IN)
Assigned to SUVEN LIFE SCIENCES LIMITED, Hyderabad-Telangana (IN)
Appl. No. 18/724,932
Filed by SUVEN LIFE SCIENCES LIMITED, Hyderabad-Telangana (IN)
PCT Filed Jan. 10, 2023, PCT No. PCT/IB2023/050192 § 371(c)(1), (2) Date Jun. 27, 2024, PCT Pub. No. WO2023/135508, PCT Pub. Date Jul. 20, 2023.
Claims priority of application No. 202241001436 (IN), filed on Jan. 11, 2022.
Prior Publication US 2025/0019386 A1, Jan. 16, 2025
Int. Cl. C07D 519/00 (2006.01); A61K 31/5025 (2006.01); A61P 1/00 (2006.01)

CPC C07D 519/00 (2013.01) [A61K 31/5025 (2013.01); A61P 1/00 (2018.01)]

7 Claims

1. A compound of formula (I)

or an isotopic form, a stereoisomer or a pharmaceutically acceptable salt thereof,

wherein:

R¹represents hydrogen, alkyl or cycloalkyl;

R²represents hydrogen, hydroxy, halogen, alkyl or cycloalkyl;

A is heterocyclic ring selected from the group consisting of:

R³is hydrogen or selected from the group consisting of:

B is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, —SO₂-alkyl, —COCH₃, —COO-alkyl, or —CO—(CH₂)_m—OH; wherein, m is an integer from 0 to 5;

Y at each occurrence is independently selected from hydrogen, hydroxy, halogen, haloalkyl, hydroxyalkyl, —COOH, —COO-alkyl, —O-alkyl, —S-alkyl or —NR^aR^b;

D represents CH or N;

n is an integer from 0 to 5;

R^aat each occurrence is independently selected from hydrogen, alkyl, cycloalkyl or alkoxy;

R^bat each occurrence is independently selected from hydrogen, alkyl, cycloalkyl or alkoxy;

R⁴represents hydrogen, hydroxy, halogen, alkyl or cycloalkyl; and

b represents 1 to 3.